Literature DB >> 8391456

Alpha-interferon inhibits adrenocortical secretion via mu 1-opioid receptors in the rat.

D Saphier1, J E Welch, H E Chuluyan.   

Abstract

The effect of recombinant human alpha-interferon on plasma corticosterone concentrations was investigated in adult male rats. Intraperitoneal (i.p.) or intracerebroventricular (i.c.v.) administration of alpha-interferon (10-10(4) U i.p., and 1-10(3) U i.c.v.) decreased basal plasma corticosterone concentrations. This effect was evident at both the peak and nadir in the circadian rhythm of hypothalamo-pituitary-adrenocortical secretory activity. The same inhibitory effect was obtained with intra-paraventricular nucleus administration of the cytokine. Furthermore, alpha-interferon attenuated the effects of stressors such as handling, 1 min of forced swimming, and sound stress in a novel environment. The effect of alpha-interferon (10(2) U i.c.v.) was blocked by prior injection of the opioid receptor antagonist, naloxone (1 mg/kg i.p.). Similarly, the effect of 10(3) U alpha-interferon administered i.p. was blocked by i.c.v. injection of naloxone (1 microgram/kg), or of the mu 1-specific receptor antagonist, naloxonazine (1 microgram). The selective delta-opioid receptor antagonist, naltrindole (1 microgram i.c.v.) and the kappa-opioid receptor antagonist, nor-binaltorphimine (1 microgram i.c.v.) both failed to prevent the inhibitory effect of alpha-interferon (10(3) U i.p.) on adrenocortical secretion. The results obtained provide further evidence for a neuromodulatory effect of alpha-interferon and that this effect is mediated by central opioid receptors of the mu 1-subtype, delta- and kappa-opioid receptors not being involved.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8391456     DOI: 10.1016/0014-2999(93)90588-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

1.  Involvement of central opioid systems in human interferon-alpha induced immobility in the mouse forced swimming test.

Authors:  M Makino; Y Kitano; C Komiyama; M Hirohashi; K Takasuna
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

2.  Effects of chronic administration of interferon alpha A/D on serotonergic receptors in rat brain.

Authors:  S Abe; T Hori; T Suzuki; A Baba; H Shiraishi; T Yamamoto
Journal:  Neurochem Res       Date:  1999-03       Impact factor: 3.996

Review 3.  Immune modulation of the hypothalamic-pituitary-adrenal (HPA) axis during viral infection.

Authors:  Marni N Silverman; Brad D Pearce; Christine A Biron; Andrew H Miller
Journal:  Viral Immunol       Date:  2005       Impact factor: 2.257

Review 4.  Harnessing cancer immunotherapy during the unexploited immediate perioperative period.

Authors:  Pini Matzner; Elad Sandbank; Elad Neeman; Oded Zmora; Vijaya Gottumukkala; Shamgar Ben-Eliyahu
Journal:  Nat Rev Clin Oncol       Date:  2020-02-17       Impact factor: 66.675

Review 5.  Endogenous opiates: 1993.

Authors:  G A Olson; R D Olson; A J Kastin
Journal:  Peptides       Date:  1994       Impact factor: 3.750

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.